Log in to save to my catalogue

SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient surviv...

SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient surviv...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5341046

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Expression of the solute carrier (SLC) transporter SLC22A3 gene is associated with overall survival of pancreatic cancer patients. This study tested whether genetic variability in SLC22A3 associates with pancreatic cancer risk and prognosis. Twenty four single nucleotide polymorphisms (SNPs) tagging the SLC22A3 gene sequence and regulatory elements...

Alternative Titles

Full title

SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5341046

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5341046

Other Identifiers

ISSN

2045-2322

E-ISSN

2045-2322

DOI

10.1038/srep43812

How to access this item